JP2006506368A5 - - Google Patents

Download PDF

Info

Publication number
JP2006506368A5
JP2006506368A5 JP2004544849A JP2004544849A JP2006506368A5 JP 2006506368 A5 JP2006506368 A5 JP 2006506368A5 JP 2004544849 A JP2004544849 A JP 2004544849A JP 2004544849 A JP2004544849 A JP 2004544849A JP 2006506368 A5 JP2006506368 A5 JP 2006506368A5
Authority
JP
Japan
Prior art keywords
acid
salt
isomer
benzhydryl
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004544849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/032275 external-priority patent/WO2004035575A1/en
Publication of JP2006506368A publication Critical patent/JP2006506368A/ja
Publication of JP2006506368A5 publication Critical patent/JP2006506368A5/ja
Pending legal-status Critical Current

Links

JP2004544849A 2002-10-16 2003-10-10 (s,s)−シス−2−ベンズヒドリル−3−ベンジルアミノキヌクリジンの調製方法 Pending JP2006506368A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41905102P 2002-10-16 2002-10-16
PCT/US2003/032275 WO2004035575A1 (en) 2002-10-16 2003-10-10 Process for the preparation of (s,s)-cis-2-benzhydryl-3-benzylaminoquinuclidine

Publications (2)

Publication Number Publication Date
JP2006506368A JP2006506368A (ja) 2006-02-23
JP2006506368A5 true JP2006506368A5 (https=) 2006-11-30

Family

ID=32108014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004544849A Pending JP2006506368A (ja) 2002-10-16 2003-10-10 (s,s)−シス−2−ベンズヒドリル−3−ベンジルアミノキヌクリジンの調製方法

Country Status (21)

Country Link
US (2) US6861526B2 (https=)
EP (1) EP1551833A4 (https=)
JP (1) JP2006506368A (https=)
KR (1) KR100739901B1 (https=)
CN (1) CN100418964C (https=)
AP (1) AP2005003288A0 (https=)
AR (1) AR041587A1 (https=)
AU (1) AU2003277353B2 (https=)
BR (1) BR0315335A (https=)
CA (1) CA2500635A1 (https=)
EA (1) EA008192B1 (https=)
HR (1) HRP20050328A2 (https=)
IS (1) IS7755A (https=)
MX (1) MXPA05004058A (https=)
PA (1) PA8586601A1 (https=)
PE (1) PE20040777A1 (https=)
PL (1) PL376218A1 (https=)
TN (1) TNSN05111A1 (https=)
UY (1) UY28024A1 (https=)
WO (1) WO2004035575A1 (https=)
ZA (1) ZA200502411B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
LT1713504T (lt) * 2004-01-30 2017-09-11 Zoetis Services Llc Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms
SI1713801T1 (sl) * 2004-02-02 2008-04-30 Pfizer Prod Inc Postopek priprave 1-(2S,3S)-2-benzhidril-N-(5-terc-butil-2-metoksibenzil)kinuklidin-3- amina
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
CN108341812A (zh) * 2017-01-23 2018-07-31 科贝源(北京)生物医药科技有限公司 一种含奎宁环化合物的制备方法
CN108341811A (zh) * 2017-01-23 2018-07-31 科贝源(北京)生物医药科技有限公司 马罗皮坦杂质的制备方法
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
WO2025172911A1 (en) * 2024-02-16 2025-08-21 Teadus Pharmaceuticals Pvt. Ltd A process for the preparation of (2s,3s)-2-benzhydryl- n-(5-tert-butyl-2-methoxybenzyl) quinuclidin-3-amine and pharmaceutically acceptable salts thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560510A (en) * 1969-03-05 1971-02-02 Aldrich Chem Co Inc 2-benzhydrylquinuclidines
US4680283A (en) 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5138060A (en) 1991-01-03 1992-08-11 Pfizer Inc. Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
UA26401C2 (uk) * 1991-05-22 1999-08-30 Пфайзер Інк. Заміщеhі 3-аміhохіhуклідиhи
AU657552B2 (en) 1991-05-31 1995-03-16 Pfizer Inc. Quinuclidine as substance P antagonists
WO1994004496A1 (en) 1992-08-19 1994-03-03 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
US5604241A (en) * 1992-10-21 1997-02-18 Pfizer Inc. Substituted benzylaminoquinuclidines as substance P antagonists
JP2656699B2 (ja) 1992-10-21 1997-09-24 ファイザー製薬株式会社 置換ベンジルアミノキヌクリジン
JP2656700B2 (ja) 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
CA2149242C (en) * 1992-11-12 1998-08-04 Fumitaka Ito Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders
IL109646A0 (en) 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
MX9706944A (es) 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.

Similar Documents

Publication Publication Date Title
JP2006506368A5 (https=)
KR100739901B1 (ko) (s,s)-시스-2-벤즈하이드릴-3-벤질아미노퀴누클리딘의제조 방법
CN110035820A (zh) 基于含氮生物聚合物的催化剂、其制备方法及其在氢化方法、还原脱卤和氧化中的用途
CN111233829A (zh) 一种具有光学活性的尼古丁的制备方法
JP2002265444A (ja) 1−(3−ベンジルオキシプロピル)−5−(2−置換プロピル)インドリン誘導体およびその使用方法
CN103664677A (zh) 一种(r,r)-福莫特罗酒石酸盐的不对称合成方法
TW200900376A (en) Method for producing 4-aminomethylbenzoic acid
CN101585798A (zh) 光学活性化合物1-(3-苯甲酰氧基丙基)-5-(2-(1-苯基乙基胺)丙基)-7-氰基吲哚啉及其制备方法和用途
JP2013512276A5 (https=)
JP4079727B2 (ja) 光学活性1−(フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル)アルキルアミンn−モノアルキル誘導体とその製造方法
EP1224161B1 (en) Nitroxy derivatives of (r) and (s)-carnitine
CN100422138C (zh) 生产旋光活性1-烷基-取代的2,2,2-三氟乙基胺的方法
JP2002544252A5 (https=)
JP3982993B2 (ja) 光学活性1−(トリフルオロメチルモノ置換フェニル)エチルアミンの精製方法
JP2005298334A (ja) 新規な中間体化合物およびそれを用いる化合物の製造方法
WO2013058241A1 (ja) (r)-2-アミノ-2-エチルヘキサノールの製造法
CN102093254B (zh) 一种二水合3-(2,2,2-三甲基肼)丙酸盐的制备方法
CN1058488C (zh) 1,3,6-三烷基六氢-1,3,6-三氮杂辛因-2-酮及其制备方法
CN113264839B (zh) 一种使用手性辅基制备左旋特布他林的方法
JP7601462B2 (ja) 不斉補助剤を使用してレボテルブタリンを調製する方法
JP2015166383A (ja) ネラメキサン又はその塩を調製する方法
JP4904945B2 (ja) 光学活性1−(フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル)アルキルアミンn−モノアルキル誘導体の製造方法
CN116693409A (zh) 一种(2s)-[4-(3-氟苄氧基)苄胺基]丙酸甲酯的制备方法
JP2007532631A (ja) 光学活性l−エリトロ−2−アミノ−1−フェニル−1−プロパノールの製造方法
JP5749261B2 (ja) 3,3,5,5−テトラメチルシクロヘキサノンを調製する方法